The 2026 Biosimilars Market: Where the $67 Billion Is Actually Going

Every year, biosimilars get talked about as a single story: patents expire, prices fall, competition arrives. Our 2026 first-half review of the 20 highest-value originator molecules worldwide tells a more complicated story - and a more useful one for anyone making sourcing, pipeline or market-entry decisions right now. Across these 20 molecules, combined worldwide sales reached roughly $67 billion in just the first six months of 2026. But that figure hides three very different markets sitting side by side: blockbusters where biosimilar competition hasn't arrived yet, molecules where it has already reshaped the entire category, and a middle group still in the early stages of erosion.

Pegfilgrastim Biosimilars: Blue Ocean or Red Ocean?

A 90% revenue drop tells you more about the pegfilgrastim market than any approval count. As the category hits extreme saturation with 10 approved biosimilars in the EU and 8 in the US, the game has changed from "can we get approved" to "can we survive consolidation?" Look behind the patent wall with Pipelinepharma’s Pipeline Intelligence. Leverage our advanced Pillar 2 Data to stress-test your portfolio, evaluate hidden market pressure, and accurately forecast future competitor density.

Sandoz's $322M biosimilar deal with Shanghai Henlius

Sandoz just committed up to $322M ($100.5M upfront) to Shanghai Henlius Biotech for ex-China rights to biosimilars of Repatha (evolocumab), Benlysta (belimumab), and Erbitux (cetuximab) — with a framework to expand to 10 molecules total. The Erbitux angle is the real signal: the drug's core patents expired years ago, yet zero biosimilars have reached market because of manufacturing complexity. That's exactly the kind of structural barrier that rewards early pipeline intelligence — knowing which manufacturers are actually capable of executing before a patent cliff opens, not after. Sandoz now sources biosimilars at 30% of its $11.1B 2025 revenue; deals like this show where the next wave of sourcing opportunity is heading.

Part 2: Generic Pipeline Intelligence vs Innovator Pipeline Intelligence - Where the Strategic Pillars Intersect

Operating with a single-pillar view of the pharmaceutical landscape exposes companies to massive commercial risks. This article examines the intersection of innovator and generic data, illustrating how cross-referenced pipeline intelligence prevents catastrophic price erosion for originators and protects generic developers from capital destruction.

Part 1: The Dual Engines of Pharma: Moving Beyond the "Innovator-Only" Bias.

Defining pharmaceutical pipeline intelligence solely through public, innovative clinical trials creates severe commercial blind spots. To protect investments, industry leaders must utilize a dual-pillar framework that balances public innovator tracking (Pillar 1) with the hidden, pre-launch generic dossier intelligence (Pillar 2) required to navigate market entry.

Samsung Biologics Expands U.S. Manufacturing Footprint Through Strategic Acquisition

Samsung Biologics expands its U.S. manufacturing presence through the acquisition of GSK’s Rockville site, strengthening capacity and supply chain resilience for pharmaceutical products.

How Pipelinepharma Simplifies Pharma Licensing for Emerging Manufacturers

Discover how Pipelinepharma helps emerging pharmaceutical manufacturers simplify global in- and out-licensing through its digital B2B platform.

A Comprehensive Guide for Licensed Manufacturers in the Pharmaceutical Industry

Your definitive guide for licensed manufacturers in pharma: FDA/DEA registration, state licenses, fees, fingerprinting, cosmetic rules. Get compliant.

A Practical Guide to Pharma Quality: From GMP to Supply Chain

Master pharma quality with a practical guide to GMP, GDP, GLP, PQS, QC, CTD and DSCSA. Build quality by design and secure your supply chain.

Decoding the Dance: How Pharmaceutical Wholesalers Really Work

Pharmaceutical wholesalers buy drugs in bulk, manage distribution, logistics, and specialized services to ensure medications reach pharmacies and hospitals.